Stockscreener 앱 받기
0.6654
2.37%
0.0154
시간 외 거래:
.65
-0.0154
-2.31%
전일 마감가:
$0.65
열려 있는:
$0.65
하루 거래량:
124.92K
Relative Volume:
0.72
시가총액:
$16.49M
수익:
$368.00K
순이익/손실:
$-9.54M
주가수익비율:
-1.3897
EPS:
-0.4788
순현금흐름:
$-9.47M
1주 성능:
+15.26%
1개월 성능:
-29.50%
6개월 성능:
-40.59%
1년 성능:
-39.51%
1일 변동 폭
$0.6409
$0.6897
1주일 범위
$0.57
$0.6897
52주 변동 폭
$0.46
$1.55
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.6654 | 16.11M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Gets Attention with GLP-1 Test on Deck - Bez Kabli
LEXX Should I Buy - Intellectia AI
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
MarketsMedicine Hat News - FinancialContent
TradingKey - TradingKey
lxrp_ex991.htm - SEC.gov
Lexaria Bioscience Releases Second Episode of Investor Video Series - Investing News Network
What Lexaria's CEO says is next for GLP-1 research in 2026 - Stock Titan
Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com India
Lexaria Updates Progress on Human Study #7 - Investing News Network
Lexaria advances semaglutide study with ethics review submission - Investing.com
Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - Investing News Network
Lexaria’s new video series zeroes in on a $75B GLP-1 market - Stock Titan
Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation - MEXC
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Th - GuruFocus
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Through 2026 - GuruFocus
Lexaria extends pharma partnership to evaluate GLP-1 technology By Investing.com - Investing.com South Africa
Lexaria extends pharma partnership to evaluate GLP-1 technology - Investing.com
Lexaria's pharma license stays active as 3 GLP-1 studies continue - Stock Titan
Lexaria's Human GLP-1 Study #5 Begins Dosing - 富途牛牛
Fit to Work: GLP-1 and Metabolic Health in the M&A Sector - Investing News Network
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - The Facts
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - The Facts
Lexaria Bioscience (LEXX) Advances Research with New Animal Stud - GuruFocus
Lexaria's 18-arm test will compare pills and capsules for two GLP-1 drugs - Stock Titan
Lexaria Bioscience: Drug Delivery Platform Innovator with Multiple Mainstream Applications - Investing News Network
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):